<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">544</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-3-60-67</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The diagnostics of blastic plasmocytoid dendritic cell neoplasm: report of five cases</article-title><trans-title-group xml:lang="ru"><trans-title>Диагностика острого лейкоза из плазмоцитоидных дендритных клеток: описание пяти случаев</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4317-2094</contrib-id><name-alternatives><name xml:lang="en"><surname>Demina</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Дёмина</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Irina А. Demina</bold>, MD, PhD, Leukemia Immunophenotyping Laboratory</p><p>1 Samory Mashela St., Moscow 117997 </p></bio><bio xml:lang="ru"><p><bold>Дёмина Ирина Андреевна</bold>, врач клинической лабораторной диагностики лаборатории иммунофенотипирования гемобластозов</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><email>idemina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kashpor</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Кашпор</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2685-674X</contrib-id><name-alternatives><name xml:lang="en"><surname>Illarionova</surname><given-names>O. I.</given-names></name><name xml:lang="ru"><surname>Илларионова</surname><given-names>О. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dubrovina</surname><given-names>M. E.</given-names></name><name xml:lang="ru"><surname>Дубровина</surname><given-names>М. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dudorova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Дудорова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2352-7716</contrib-id><name-alternatives><name xml:lang="en"><surname>Olshanskaya</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Ольшанская</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0016-6698</contrib-id><name-alternatives><name xml:lang="en"><surname>Maschan</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Масчан</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0889-6986</contrib-id><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-10-08" publication-format="electronic"><day>08</day><month>10</month><year>2021</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>60</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2021-10-08"><day>08</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-08"><day>08</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/544">https://hemoncim.com/jour/article/view/544</self-uri><abstract xml:lang="en"><p>The diagnosis of rare hematological disorders requires a comprehensive clinical and laboratory investigation with careful interpretation of all test results. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one of such rare entities. We have performed a retrospective analysis of the results of immunophenotyping, cytomorphology and cytogenetics of bone marrow tumor cells from 5 patients with BPDCN aged from 8 to 51 years. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. No specific characteristics of blasts were found. No correlation with the treatment and outcomes was noted as well: 3 patients died of progression or relapse (2 and 1, respectively). Bone marrow immunophenotyping is probably the most valuable laboratory test which allows physicians to establish the proper diagnosis in the absence of skin lesions. Flow cytometry immunophenotyping is the only technique used to determine the antigen profile that enables us to distinguish normal plasmacytoid dendritic cells from tumor ones by the presence (or absence) of the expression of CD2, CD7, CD38, CD56, CD303 etc. In the present paper, we provide a detailed description of five cases of BPDCN and main methods for flow cytometry data analysis. The parents of the patients agreed to use the information, including photos of children, in scientific research and publications.</p></abstract><trans-abstract xml:lang="ru"><p>Диагностика редких форм онкогематологических заболеваний требует всестороннего обследования и внимательного изучения всех результатов. Одним из таких заболеваний, которое при первичной диагностике может быть в некоторых случаях ошибочно отнесено к дерматологическим за счет агрессивного поражения кожи, является лейкоз из плазмоцитоидных дендритных клеток (ПДКЛ). Нами ретроспективно проанализированы данные иммунофенотипического, морфологического и цитогенетического исследований опухолевых клеток костного мозга 5 пациентов в возрасте от 8 лет до 51 года с диагнозом ПДКЛ, выявленных в период с апреля 2013 г. по март 2020 г. Данное исследование одобрено независимым этическим комитетом и утверждено решением ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева. Не было обнаружено выраженных признаков, позволяющих однозначно охарактеризовать бластные клетки. Также не было выявлено связи между выбранной тактикой лечения и исходами заболевания на настоящий момент: 3 пациента скончались (2 в прогрессии заболевания, 1 в рецидиве), 2 находятся в ремиссии. При отсутствии выраженных кожных проявлений важнейшим исследованием при диагностике ПДКЛ становится иммунофенотипирование клеток костного мозга, позволяющее установить диагноз при малой информативности других методов. Только иммунофенотипирование дает возможность определить антигенный профиль, отличающий нормальные дендритные клетки от опухолевых по сочетанию наличия и отсутствия маркеров CD2, CD7, CD38, CD56, CD303 и др. В данной работе мы подробно описываем 5 клинических случаев ПДКЛ и основные подходы к оценке цитометрических данных при этой патологии, а также редкий случай коэкспрессии iCD79a. Родители пациентов дали согласие на использование информации, в том числе фотографий детей, в научных исследованиях и публикациях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>blastic plasmacytoid dendritic cell neoplasm</kwd><kwd>immunophenotyping</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лейкоз из плазмоцитоидных дендритных клеток</kwd><kwd>иммунофенотипирование</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405.</mixed-citation><mixed-citation xml:lang="ru">Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Khoury J.D. Blastic Plasmacytoid Dendritic Cell Neoplasm. Curr Hematol Malig Rep 2018; 13 (6): 477–83.</mixed-citation><mixed-citation xml:lang="ru">Khoury J.D. Blastic Plasmacytoid Dendritic Cell Neoplasm. Curr Hematol Malig Rep 2018; 13 (6): 477–83.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Facchetti F., Petrella T., Pileri S. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon; 2017: 174–7.</mixed-citation><mixed-citation xml:lang="ru">Facchetti F., Petrella T., Pileri S. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon; 2017: 174–7.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Sapienza M.R., Pileri A., Derenzini E., Melle F., Motta G., Fiori S., et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers 2019; 11 (5): 595.</mixed-citation><mixed-citation xml:lang="ru">Sapienza M.R., Pileri A., Derenzini E., Melle F., Motta G., Fiori S., et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers 2019; 11 (5): 595.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Julia F., Petrella T., Beylot-Barry M., Bagot M., Lipsker D., Machet L., et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 2013; 169 (3): 579–86.</mixed-citation><mixed-citation xml:lang="ru">Julia F., Petrella T., Beylot-Barry M., Bagot M., Lipsker D., Machet L., et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 2013; 169 (3): 579–86.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Pagano L., Valentini C.G., Pulsoni A., Fisogni S., Carluccio P., Mannelli F., et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an italian multicenter study. Haematologica 2013; 98 (2): 239–46.</mixed-citation><mixed-citation xml:lang="ru">Pagano L., Valentini C.G., Pulsoni A., Fisogni S., Carluccio P., Mannelli F., et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an italian multicenter study. Haematologica 2013; 98 (2): 239–46.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Berti E., Lucioni M., Onida F., Novara F., Caprini E., Fiandrino G., et al. Blastic plasmacytoid dendritic cell neoplasm: clinical, immunohistochemical and molecular evaluation of 23 cases with primary cutaneous involvement. Blood 2011; 118: 3565.</mixed-citation><mixed-citation xml:lang="ru">Berti E., Lucioni M., Onida F., Novara F., Caprini E., Fiandrino G., et al. Blastic plasmacytoid dendritic cell neoplasm: clinical, immunohistochemical and molecular evaluation of 23 cases with primary cutaneous involvement. Blood 2011; 118: 3565.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Feuillard J., Jacob M.C., Valensi F., Maynadié M., Gressin R., Chaperot L., et al. Clinical and biologic features of CD4+ CD56+ malignancies. Blood 2002; 99 (5): 1556–63.</mixed-citation><mixed-citation xml:lang="ru">Feuillard J., Jacob M.C., Valensi F., Maynadié M., Gressin R., Chaperot L., et al. Clinical and biologic features of CD4+ CD56+ malignancies. Blood 2002; 99 (5): 1556–63.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Sapienza M.R., Pileri A., Derenzini E., Melle F., Motta G., Fiori S., et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers 2019; 11 (5): 595.</mixed-citation><mixed-citation xml:lang="ru">Sapienza M.R., Pileri A., Derenzini E., Melle F., Motta G., Fiori S., et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers 2019; 11 (5): 595.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Kim M.J.M., Nasr A., Kabir B., de Nanassy J., Tang K., Menzies-Toman D., et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review. Pediatr Hematol Oncol 2017; 39 (7): 528–37.</mixed-citation><mixed-citation xml:lang="ru">Kim M.J.M., Nasr A., Kabir B., de Nanassy J., Tang K., Menzies-Toman D., et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review. Pediatr Hematol Oncol 2017; 39 (7): 528–37.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Garnache-Ottou F., Vidal C., Biichlé S., Renosi F., Poret E., Pagadoy M., et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv 2019; 3 (24): 4238–51.</mixed-citation><mixed-citation xml:lang="ru">Garnache-Ottou F., Vidal C., Biichlé S., Renosi F., Poret E., Pagadoy M., et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv 2019; 3 (24): 4238–51.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Lyapichev K.A., Sukswai N., Konoplev S., Khoury J.D. Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles. Ann Hematol 2019; 98 (9): 2221–2.</mixed-citation><mixed-citation xml:lang="ru">Lyapichev K.A., Sukswai N., Konoplev S., Khoury J.D. Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles. Ann Hematol 2019; 98 (9): 2221–2.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Fu Y., Fesler M., Mahmud G., Bernreuter K., Jia D., Batanian J.R. Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Gene Ther 2013; 206 (7–8): 293–8.</mixed-citation><mixed-citation xml:lang="ru">Fu Y., Fesler M., Mahmud G., Bernreuter K., Jia D., Batanian J.R. Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Gene Ther 2013; 206 (7–8): 293–8.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Sukswai N., Aung P.P., Yin C.C., Li S., Wang W., Wang S.A., et al. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol 2019; 43 (10): 1429–37.</mixed-citation><mixed-citation xml:lang="ru">Sukswai N., Aung P.P., Yin C.C., Li S., Wang W., Wang S.A., et al. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol 2019; 43 (10): 1429–37.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Tsagarakis N. J., Paterakis G. Dendritic Cell Leukemia: a Review. Curr Oncol 2020; 22 (6): 55.</mixed-citation><mixed-citation xml:lang="ru">Tsagarakis N. J., Paterakis G. Dendritic Cell Leukemia: a Review. Curr Oncol 2020; 22 (6): 55.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Alayed K., Patel K.P., Konoplev S., Singh R.R., Routbort M.J., Reddy N., et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 2013; 88 (12): 1055–61.</mixed-citation><mixed-citation xml:lang="ru">Alayed K., Patel K.P., Konoplev S., Singh R.R., Routbort M.J., Reddy N., et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 2013; 88 (12): 1055–61.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Kalina T., Flores-Montero J., Van Der Velden V.H.J., Martin-Ayuso M., Böttcher S., Ritgen M., et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26 (9): 1986–2010.</mixed-citation><mixed-citation xml:lang="ru">Kalina T., Flores-Montero J., Van Der Velden V.H.J., Martin-Ayuso M., Böttcher S., Ritgen M., et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26 (9): 1986–2010.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Новикова И.А., Вержбицкая Т.Ю., Мовчан Л.В., Цаур Г.А., Белевцев М.В., Попов А.М. Стандарт российско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей. Онкогематология 2018; 13 (1): 73–82.</mixed-citation><mixed-citation xml:lang="ru">Новикова И.А., Вержбицкая Т.Ю., Мовчан Л.В., Цаур Г.А., Белевцев М.В., Попов А.М. Стандарт российско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей. Онкогематология 2018; 13 (1): 73–82.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Sakamoto K., Katayama R., Asaka R., Sakata S., Baba S., Nakasone H., et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia 2018; 32 (12): 2590–603.</mixed-citation><mixed-citation xml:lang="ru">Sakamoto K., Katayama R., Asaka R., Sakata S., Baba S., Nakasone H., et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia 2018; 32 (12): 2590–603.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Cota C., Vale E., Viana I., Requena L., Ferrara G., Anemona L., et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm—morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34 (1): 75–87.</mixed-citation><mixed-citation xml:lang="ru">Cota C., Vale E., Viana I., Requena L., Ferrara G., Anemona L., et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm—morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34 (1): 75–87.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Gao N.A., Wang X.X., Sun J.R., Yu W.Z., Guo N.J. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report. Exp Ther Med 2015; 9 (4): 1109–12.</mixed-citation><mixed-citation xml:lang="ru">Gao N.A., Wang X.X., Sun J.R., Yu W.Z., Guo N.J. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report. Exp Ther Med 2015; 9 (4): 1109–12.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Tokuda K., Eguchi-Ishimae M., Yagi C., Kawabe M., Moritani K., Niiya T., et al. CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. Genes Chromosom Cancer 2014; 53 (1): 78–89.</mixed-citation><mixed-citation xml:lang="ru">Tokuda K., Eguchi-Ishimae M., Yagi C., Kawabe M., Moritani K., Niiya T., et al. CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. Genes Chromosom Cancer 2014; 53 (1): 78–89.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Yang N., Huh J., Chung W.S., Cho M.S., Ryu K.H., Chung H.S. KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm. Cancer genetics 2015; 208 (9): 464–7.</mixed-citation><mixed-citation xml:lang="ru">Yang N., Huh J., Chung W.S., Cho M.S., Ryu K.H., Chung H.S. KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm. Cancer genetics 2015; 208 (9): 464–7.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Weir E.G., Boowitz M.J. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001; 38 (2): 124–38.</mixed-citation><mixed-citation xml:lang="ru">Weir E.G., Boowitz M.J. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001; 38 (2): 124–38.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Guru G.M., Pemmaraju N., Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018; 73: 21–3.</mixed-citation><mixed-citation xml:lang="ru">Guru G.M., Pemmaraju N., Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018; 73: 21–3.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Lee J.M., Kim I.S., Lee J.N., Park S.H., Kim H.H., Chang C.L., et al. Acute myeloid leukemia with MLL rearrangement and CD4+/CD56+ expression can be misdiagnosed as Blastic Plasmacytoid dendritic cell neoplasm: two case reports. Ann Lab Med 2016; 36 (5): 494–7.</mixed-citation><mixed-citation xml:lang="ru">Lee J.M., Kim I.S., Lee J.N., Park S.H., Kim H.H., Chang C.L., et al. Acute myeloid leukemia with MLL rearrangement and CD4+/CD56+ expression can be misdiagnosed as Blastic Plasmacytoid dendritic cell neoplasm: two case reports. Ann Lab Med 2016; 36 (5): 494–7.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Lee S.E., Park H.Y., Kwon D., Jeon Y.K., Kim W.Y. Blastic plasmacytoid dendritic cell neoplasm with unusual extracutaneous manifestation: two case reports and literature review. Medicine (Baltimore) 2019; 98 (6): e14344.</mixed-citation><mixed-citation xml:lang="ru">Lee S.E., Park H.Y., Kwon D., Jeon Y.K., Kim W.Y. Blastic plasmacytoid dendritic cell neoplasm with unusual extracutaneous manifestation: two case reports and literature review. Medicine (Baltimore) 2019; 98 (6): e14344.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Laribi K., Baugier de Materre A., Sobh M., Cerroni L., Valentini C.G., Aoki T., et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv 2020; 4 (19): 4838–48.</mixed-citation><mixed-citation xml:lang="ru">Laribi K., Baugier de Materre A., Sobh M., Cerroni L., Valentini C.G., Aoki T., et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv 2020; 4 (19): 4838–48.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332 (6029): 600–3.</mixed-citation><mixed-citation xml:lang="ru">Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332 (6029): 600–3.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Julia F., Dalle S., Duru G., Balme B., Vergier B., Ortonne N., et al. Blastic plasmacytoid dendritic cell neoplasms: clinic-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 2014; 38 (5): 673–80.</mixed-citation><mixed-citation xml:lang="ru">Julia F., Dalle S., Duru G., Balme B., Vergier B., Ortonne N., et al. Blastic plasmacytoid dendritic cell neoplasms: clinic-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 2014; 38 (5): 673–80.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Wang W., Khoury J.D., Miranda R.N., Jorgensen J.L., Xu J., Loghavi S., et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 2021; 106 (4): 1047–55.</mixed-citation><mixed-citation xml:lang="ru">Wang W., Khoury J.D., Miranda R.N., Jorgensen J.L., Xu J., Loghavi S., et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 2021; 106 (4): 1047–55.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Comeau M.R., Maliszewski C.R., Galibert L. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol 2002; 169 (1): 75–83.</mixed-citation><mixed-citation xml:lang="ru">Comeau M.R., Maliszewski C.R., Galibert L. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol 2002; 169 (1): 75–83.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Osaki Y., Yokohama A., Saito A., Tahara K., Yanagisawa K., Ogawa Y., et al. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One 2013; 8 (11): e81722.</mixed-citation><mixed-citation xml:lang="ru">Osaki Y., Yokohama A., Saito A., Tahara K., Yanagisawa K., Ogawa Y., et al. Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One 2013; 8 (11): e81722.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Petrella T., Comeau M.R., Maynadié M., Couillault G., De Muret A., Maliszewski C.R., et al. Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26 (7): 852–62.</mixed-citation><mixed-citation xml:lang="ru">Petrella T., Comeau M.R., Maynadié M., Couillault G., De Muret A., Maliszewski C.R., et al. Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26 (7): 852–62.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
